Revolutionary intracellular screening platform creates new opportunities to discover first-in-class therapeutics to address challenging disease targets
Redefining Drug Discovery
Our mission is to use our Microcycle® platform to redefine the landscape of targets that can be addressed by small molecule drugs and to deploy this platform to build a pipeline of high-value cancer therapeutics.
Our Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for small molecule hit-to-lead programmes.
Challenging cancer targets
We are deploying our platform to build a pipeline of first-in-class small molecules to address high priority cancer targets that have evaded conventional discovery approaches.